1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Summary
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celyad Oncology Doses First Patient in Trial of Colorectal Cancer Treatment

12/16/2021 | 04:28am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
CELYAD ONCOLOGY SA 4.61% 1.95 Real-time Quote.-46.97%
MERCK & CO., INC. -2.07% 91.82 Delayed Quote.22.33%
All news about CELYAD ONCOLOGY SA
05/17Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
AQ
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : 1st quarter results
CO
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
04/01CELYAD ONCOLOGY SA : Ordinary general shareholder meeting
CO
03/25TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
CI
03/25CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
PU
03/25CELYAD ONCOLOGY : Letter to Shareholders – March 2022
PU
03/24Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/24Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
AQ
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Financials
Sales 2022 7,27 M 7,76 M 7,76 M
Net income 2022 -34,7 M -37,1 M -37,1 M
Net cash 2022 9,67 M 10,3 M 10,3 M
P/E ratio 2022 -1,38x
Yield 2022 -
Capitalization 42,1 M 45,2 M 45,0 M
EV / Sales 2022 4,46x
Capi. / Sales 2023 4,77x
Nbr of Employees 98
Free-Float 60,2%
Chart CELYAD ONCOLOGY SA
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | CYAD | BE0974260896 | MarketScreener
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,86 €
Average target price 11,00 €
Spread / Average Target 490%
EPS Revisions
Managers and Directors
Filippo Joseph Petti Director, Chief Executive & Financial Officer
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Peggy Sotiropoulou Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CELYAD ONCOLOGY SA-46.97%45
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232